International Stem Cell Corporation (ISCO)
USD 0.12
(20.0%)
USD 0.12
(20.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -663 Thousand USD | -238.27% |
| 2022 | -196 Thousand USD | 89.8% |
| 2021 | -1.92 Million USD | 31.83% |
| 2020 | -2.81 Million USD | 50.8% |
| 2019 | -5.72 Million USD | -64.88% |
| 2018 | -3.47 Million USD | 29.7% |
| 2017 | -4.94 Million USD | -1.88% |
| 2016 | -4.85 Million USD | -6.29% |
| 2015 | -4.56 Million USD | 47.42% |
| 2014 | -8.68 Million USD | -15.03% |
| 2013 | -7.54 Million USD | 23.1% |
| 2012 | -9.81 Million USD | 13.58% |
| 2011 | -11.35 Million USD | -8.54% |
| 2010 | -10.46 Million USD | -45.33% |
| 2009 | -7.19 Million USD | -30.11% |
| 2008 | -5.53 Million USD | 8.9% |
| 2007 | -6.07 Million USD | -6.26% |
| 2006 | -5.71 Million USD | -68797.31% |
| 2005 | -8296.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -178 Thousand USD | 58.02% |
| 2024 Q2 | 149 Thousand USD | 183.71% |
| 2023 Q4 | -424 Thousand USD | -337.11% |
| 2023 Q1 | 2000.00 USD | -96.72% |
| 2023 Q2 | -144 Thousand USD | -7300.0% |
| 2023 FY | -663 Thousand USD | -238.27% |
| 2023 Q3 | -97 Thousand USD | 32.64% |
| 2022 Q2 | 31 Thousand USD | 24.0% |
| 2022 FY | -196 Thousand USD | 89.8% |
| 2022 Q4 | 61 Thousand USD | 120.33% |
| 2022 Q3 | -300 Thousand USD | -1067.74% |
| 2022 Q1 | 25 Thousand USD | 107.74% |
| 2021 Q2 | -406 Thousand USD | 28.4% |
| 2021 Q3 | -623 Thousand USD | -53.45% |
| 2021 FY | -1.92 Million USD | 31.83% |
| 2021 Q1 | -567 Thousand USD | 22.65% |
| 2021 Q4 | -323 Thousand USD | 48.15% |
| 2020 Q2 | -832 Thousand USD | -82.86% |
| 2020 FY | -2.81 Million USD | 50.8% |
| 2020 Q3 | -798 Thousand USD | 4.09% |
| 2020 Q4 | -733 Thousand USD | 8.15% |
| 2020 Q1 | -455 Thousand USD | 81.68% |
| 2019 Q1 | -1.48 Million USD | -18.17% |
| 2019 Q4 | -2.48 Million USD | -205.54% |
| 2019 FY | -5.72 Million USD | -64.88% |
| 2019 Q2 | -941 Thousand USD | 36.8% |
| 2019 Q3 | -813 Thousand USD | 13.6% |
| 2018 Q2 | -366 Thousand USD | 69.11% |
| 2018 Q4 | -1.26 Million USD | -90.05% |
| 2018 FY | -3.47 Million USD | 29.7% |
| 2018 Q1 | -1.18 Million USD | 38.41% |
| 2018 Q3 | -663 Thousand USD | -81.15% |
| 2017 Q3 | -970 Thousand USD | 3.19% |
| 2017 FY | -4.94 Million USD | -1.88% |
| 2017 Q1 | -1.04 Million USD | 10.83% |
| 2017 Q4 | -1.92 Million USD | -98.35% |
| 2017 Q2 | -1 Million USD | 4.21% |
| 2016 FY | -4.85 Million USD | -6.29% |
| 2016 Q4 | -1.17 Million USD | 7.05% |
| 2016 Q3 | -1.26 Million USD | -1.04% |
| 2016 Q2 | -1.24 Million USD | -7.03% |
| 2016 Q1 | -1.16 Million USD | -12.32% |
| 2015 Q3 | -622 Thousand USD | 33.62% |
| 2015 Q2 | -937 Thousand USD | 52.34% |
| 2015 FY | -4.56 Million USD | 47.42% |
| 2015 Q1 | -1.96 Million USD | 15.91% |
| 2015 Q4 | -1.03 Million USD | -67.04% |
| 2014 FY | -8.68 Million USD | -15.03% |
| 2014 Q4 | -2.33 Million USD | -14.95% |
| 2014 Q1 | -2.06 Million USD | -6.61% |
| 2014 Q2 | -2.24 Million USD | -8.62% |
| 2014 Q3 | -2.03 Million USD | 9.32% |
| 2013 Q4 | -1.93 Million USD | -13.74% |
| 2013 FY | -7.54 Million USD | 23.1% |
| 2013 Q1 | -1.7 Million USD | 34.34% |
| 2013 Q2 | -2.19 Million USD | -28.94% |
| 2013 Q3 | -1.7 Million USD | 22.31% |
| 2012 Q4 | -2.58 Million USD | -24.47% |
| 2012 FY | -9.81 Million USD | 13.58% |
| 2012 Q1 | -2.71 Million USD | 6.47% |
| 2012 Q2 | -2.42 Million USD | 10.81% |
| 2012 Q3 | -2.08 Million USD | 14.23% |
| 2011 Q3 | -3.12 Million USD | -9.2% |
| 2011 Q2 | -2.85 Million USD | -23.55% |
| 2011 FY | -11.35 Million USD | -8.54% |
| 2011 Q1 | -2.31 Million USD | 14.41% |
| 2011 Q4 | -2.9 Million USD | 6.86% |
| 2010 Q2 | -2.85 Million USD | -31.59% |
| 2010 Q1 | -2.16 Million USD | -49.55% |
| 2010 FY | -10.46 Million USD | -45.33% |
| 2010 Q3 | -2.94 Million USD | -3.08% |
| 2010 Q4 | -2.7 Million USD | 8.06% |
| 2009 Q1 | -1.88 Million USD | -46.18% |
| 2009 Q4 | -1.44 Million USD | 29.58% |
| 2009 Q3 | -2.05 Million USD | 1.9% |
| 2009 Q2 | -2.09 Million USD | -11.33% |
| 2009 FY | -7.19 Million USD | -30.11% |
| 2008 Q4 | -1.28 Million USD | -34.66% |
| 2008 Q2 | -1.67 Million USD | -3.93% |
| 2008 Q1 | -1.61 Million USD | -5.54% |
| 2008 FY | -5.53 Million USD | 8.9% |
| 2008 Q3 | -957.38 Thousand USD | 42.84% |
| 2007 FY | -6.07 Million USD | -6.26% |
| 2007 Q4 | -1.52 Million USD | -4.04% |
| 2007 Q1 | -1.72 Million USD | 69.61% |
| 2007 Q2 | -1.73 Million USD | -0.08% |
| 2007 Q3 | -1.46 Million USD | 15.22% |
| 2006 Q2 | -1122.00 USD | 91.19% |
| 2006 FY | -5.71 Million USD | -68797.31% |
| 2006 Q1 | -12.74 Thousand USD | 0.0% |
| 2006 Q4 | -5.69 Million USD | -54688.87% |
| 2006 Q3 | -10.38 Thousand USD | -825.85% |
| 2005 FY | -8296.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 50.353% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 86.857% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 96.285% |
| Nascent Biotech, Inc. | -2.22 Million USD | 70.267% |
| Rebus Holdings, Inc. | -664 Thousand USD | 0.151% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.81% |
| Qrons Inc. | -643.67 Thousand USD | -3.002% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -70.188% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.806% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -59.575% |
| Skye Bioscience, Inc. | -13.67 Million USD | 95.151% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.076% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 113.49% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -153.318% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.126% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 76.741% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 56.837% |
| Mesoblast Limited | -84.14 Million USD | 99.212% |
| Marizyme, Inc. | -34.08 Million USD | 98.055% |
| Genus plc | 6.4 Million USD | 110.359% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 106.805% |
| Pharming Group N.V. | -4.87 Million USD | 86.413% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 66.624% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 28.815% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 92.06% |
| ContraFect Corporation | -56.88 Million USD | 98.835% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 85.444% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 52.71% |
| IMV Inc. | -38.67 Million USD | 98.286% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 75.898% |
| MultiCell Technologies, Inc. | -722.81 USD | -91625.35% |
| ONE Bio Corp. | 13.68 Million USD | 104.846% |
| Accustem Sciences Inc. | -3.74 Million USD | 82.303% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.876% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -37.249% |
| Q BioMed Inc. | -3.44 Million USD | 80.758% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 118.729% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 74.767% |
| Biomind Labs Inc. | -1 Million USD | 34.331% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.794% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 77.148% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 90.027% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 64.438% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -2113.542% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 95.822% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 65.694% |
| GB Sciences, Inc. | -1.42 Million USD | 53.327% |
| Alpha Cognition Inc. | -9.7 Million USD | 93.169% |
| HST Global, Inc. | -140.9 Thousand USD | -370.523% |
| CSL Limited | 3.7 Billion USD | 100.018% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 41.062% |
| Halberd Corporation | -75.05 Thousand USD | -783.411% |
| Enzolytics Inc. | -2.14 Million USD | 69.146% |
| Agentix Corp. | -1.37 Million USD | 51.668% |
| Resverlogix Corp. | -12.74 Million USD | 94.8% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 79.074% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.844% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 36.494% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 77.29% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 58.021% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 80.529% |
| AVAX Technologies, Inc. | 6.69 Million USD | 109.906% |
| Zenith Capital Corp. | -8.94 Million USD | 92.586% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.841% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3705.752% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 72.997% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -286.567% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 66.929% |
| Kadimastem Ltd | -3.04 Million USD | 78.193% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 32.626% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 47.213% |
| BioStem Technologies, Inc. | -7.77 Million USD | 91.477% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -265.319% |
| LadRx Corporation | -3.82 Million USD | 82.66% |
| Cell Source, Inc. | -4.32 Million USD | 84.672% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 3.486% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 3.486% |
| NovAccess Global Inc. | -2.46 Million USD | 73.123% |
| Affymax, Inc. | -15.04 Million USD | 95.594% |
| Itoco Inc. | -919.14 Thousand USD | 27.867% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 84.357% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 40.751% |
| Mobile Lads Corp. | -554.55 Thousand USD | -19.556% |
| CytoDyn Inc. | -18.05 Million USD | 96.328% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -2534.088% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -201.257% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -17.403% |
| SYBLEU INC | -149.18 Thousand USD | -344.43% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 63.498% |
| Bioxytran, Inc. | -3.82 Million USD | 82.645% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1159.498% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -3159.587% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.172% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 59.023% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 9.898% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 78.689% |
| Neutra Corp. | -229.48 Thousand USD | -188.907% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 96.22% |
| PureTech Health plc | -146.19 Million USD | 99.547% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 96.915% |
| IXICO plc | -1.43 Million USD | 53.862% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 93.014% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.456% |
| CSL Limited | 3.81 Billion USD | 100.017% |
| Cellectis S.A. | -108.85 Million USD | 99.391% |